OCT 06, 2016 10:30 AM PDT

Precision Genomics and Precision Medicine for Immuno-Oncology

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Manager, Field Applications Scientist, Personalis, Inc.
    Biography
      Erin Newburn, MS, PhD, joined Personalis as a Field Application Scientist in 2013 with over 12 years of research experience in the areas of molecular biology, genetics, and biotechnology. As the Field Applications Manager, Erin's team has the responsibility for providing both pre and post-sale technical support for the Personalis ACE Cancer Portfolio. She completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.

    Abstract:

    Tumors often evade immune destruction by adapting and circumventing immune checkpoints to create resistance.  This adaptive immunity can be reversed to stimulate the endogenous immune response.  Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, making it able to recognize these cancer cells and destroy them.  Due to the rapid expansion of genomic technologies, Precision Medicine in cancer is leading to exciting therapeutic capabilities.  By a deeper understanding of the tumor genetics, patients can be prescribed more effective therapies or even avoid those that may be potentially adverse.  This webinar will highlight the current renaissance in immunotherapy and discuss the expanding role of both genomics and transcriptomics in providing more personalized cancer care.

    Learning Objectives:

    • Review of the opportunities for precision medicine in immuno-oncology from checkpoint modulators to adoptive cell therapy
    • Understanding the key accuracy challenges in utilizing technologies like NGS for the development of particular immunotherapies such as personalized cancer vaccines
    • Evaluation of the current methods to predict the likelihood of positive response to immunotherapy


     


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    Loading Comments...
    Show Resources